Furthermore, our data show the additional anti-tumor effect of asciminib when combined with KIRA8, which supports previous studies showing the critical role of the UPR balance with IRE1α and PERK signaling in maintaining secretory cancers, which are susceptible to ER stress [8,10]. The gene discussed is EIF2AK3; the disease is cancer.